Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Investing Activities (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Cash from Investing Activities for 3 consecutive years, with $43.2 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Cash from Investing Activities rose 750.45% year-over-year to $43.2 million, compared with a TTM value of $130.6 million through Dec 2021, up 146.37%, and an annual FY2024 reading of $17.0 million, up 3.81% over the prior year.
  • Cash from Investing Activities was $43.2 million for Q4 2021 at Black Diamond Therapeutics, up from $35.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $48.2 million in Q2 2021 and bottomed at -$279.6 million in Q2 2020.
  • Average Cash from Investing Activities over 3 years is -$13.7 million, with a median of $2000.0 recorded in 2019.
  • Peak annual rise in Cash from Investing Activities hit 41890.91% in 2020, while the deepest fall reached 13982100.0% in 2020.
  • Year by year, Cash from Investing Activities stood at -$2000.0 in 2019, then crashed by 332300.0% to -$6.6 million in 2020, then surged by 750.45% to $43.2 million in 2021.
  • Business Quant data shows Cash from Investing Activities for BDTX at $43.2 million in Q4 2021, $35.7 million in Q3 2021, and $48.2 million in Q2 2021.